论文部分内容阅读
目的:研究莫西沙星治疗社区获得性下呼吸道感染老年患者的耐受性和安全性。方法:将197例社区获得性下呼吸道感染老年患者纳入研究,其中男性104例,女性93例,平均年龄(73±11)岁。患者静脉给予莫西沙星400mg/d,7～10d,继口服莫西沙星400mg/d,3～6d。疗程约2周。观察莫西沙星治疗的耐受性和不良反应。结果:197例患者中194例完成2周治疗,有3例因出现神经精神不良反应和皮疹中断治疗。194例中痊愈135例,显效42例,进步17例;出现不良反应24例,主要为轻度的神经精神及消化系统不良反应。结论:莫西沙星是治疗社区获得性下呼吸道感染较为有效和安全的药物,老年患者能良好耐受。
Objective: To investigate the tolerability and safety of moxifloxacin in elderly patients with community-acquired lower respiratory tract infection. METHODS: A total of 197 elderly patients with community-acquired lower respiratory tract infection were enrolled in the study, including 104 males and 93 females, with an average age of 73 ± 11 years. Patients were given moxifloxacin intravenously 400mg / d, 7 ~ 10d, followed by oral moxifloxacin 400mg / d, 3 ~ 6d. Course of about 2 weeks. To observe the moxifloxacin treatment tolerance and adverse reactions. RESULTS: Of the 197 patients, 194 completed 2 weeks of treatment and 3 received neuropsychiatric reactions and rashes discontinuation. In 194 cases, 135 cases were cured, 42 cases were markedly improved and 17 cases were improved. There were 24 adverse reactions, which were mainly mild neuropsychiatric and digestive system adverse reactions. CONCLUSIONS: Moxifloxacin is a more effective and safe drug for the treatment of community-acquired lower respiratory tract infections and is well tolerated in elderly patients.